---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-23-000014"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T11:50:14.715402+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech appoints Catherine Mazzacco to Board of Directors

## Summary
- Board expanded from 8 to 9 directors; Catherine Mazzacco appointed as independent Class I director effective March 6, 2023.
- Mazzacco will serve on the Nominating and Corporate Governance committee and stand for election at 2024 annual meeting.
- She previously served as CEO & President of LEO Pharma and SVP at GE HealthCare, with 25+ years at Abbott Laboratories.
- No material transactions or arrangements between Mazzacco and the company; standard director compensation applies.

## SEC filing metadata
- accession: 0001711279-23-000014
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127923000014/0001711279-23-000014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127923000014/krys-20230306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-23-000014
- JSON: https://secwatch.observer/filing/0001711279-23-000014.json
- Plain text: https://secwatch.observer/filing/0001711279-23-000014.txt

## Key facts
- Executive change
  Catherine Mazzacco was appointed as independent member of the Board at Krystal Biotech, Inc..
  - Action: appointed
  - Role: independent member of the Board
  source text: On March 6, 2023, the Board of Directors (the “Board”) of Krystal Biotech, Inc. (the “Company”) approved an increase in the size of the Board from eight (8) directors to nine (9) directors and appointed Catherine Mazzacco as an independent member of the Board to fill the vacancy created by the increase in the size of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711279/000171127923000014/0001711279-23-000014-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.